Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.

Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy.

Heier CR, Yu Q, Fiorillo AA, Tully CB, Tucker A, Mazala DA, Uaesoontrachoon K, Srinivassane S, Damsker JM, Hoffman EP, Nagaraju K, Spurney CF.

Life Sci Alliance. 2019 Feb 11;2(1). pii: e201800186. doi: 10.26508/lsa.201800186. Print 2019 Feb.

2.

Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy.

Mavroudis PD, van den Anker J, Conklin LS, Damsker JM, Hoffman EP, Nagaraju K, Clemens PR, Jusko WJ.

J Clin Pharmacol. 2019 Feb 11. doi: 10.1002/jcph.1388. [Epub ahead of print]

PMID:
30742306
3.

Radiological analysis of the sella turcica and its correlations with body mass index in a North Indian population.

Gargi V, Ravi Prakash SM, Nagaraju K, Malik S, Goel S, Gupta S.

Oral Radiol. 2018 Jun 19. doi: 10.1007/s11282-018-0337-9. [Epub ahead of print]

PMID:
30484194
4.

Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis.

Conklin LS, Merkel PA, Pachman LM, Parikh H, Tawalbeh S, Damsker JM, Cuthbertson DD, Morgan GA, Monach PA, Hathout Y, Nagaraju K, van den Anker J, McAlear CA, Hoffman EP.

Steroids. 2018 Dec;140:159-166. doi: 10.1016/j.steroids.2018.10.008. Epub 2018 Oct 21.

5.

Oxidative coupling strategies for the synthesis of indole alkaloids.

Nagaraju K, Ma D.

Chem Soc Rev. 2018 Oct 29;47(21):8018-8029. doi: 10.1039/c8cs00305j. Review.

PMID:
30221274
6.

Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug.

Conklin LS, Damsker JM, Hoffman EP, Jusko WJ, Mavroudis PD, Schwartz BD, Mengle-Gaw LJ, Smith EC, Mah JK, Guglieri M, Nevo Y, Kuntz N, McDonald CM, Tulinius M, Ryan MM, Webster R, Castro D, Finkel RS, Smith AL, Morgenroth LP, Arrieta A, Shimony M, Jaros M, Shale P, McCall JM, Hathout Y, Nagaraju K, van den Anker J, Ward LM, Ahmet A, Cornish MR, Clemens PR.

Pharmacol Res. 2018 Oct;136:140-150. doi: 10.1016/j.phrs.2018.09.007. Epub 2018 Sep 13.

7.

"Of Mice and Measures": A Project to Improve How We Advance Duchenne Muscular Dystrophy Therapies to the Clinic.

Gordish-Dressman H, Willmann R, Dalle Pazze L, Kreibich A, van Putten M, Heydemann A, Bogdanik L, Lutz C, Davies K, Demonbruen AR, Duan D, Elsey D, Fukada SI, Girgenrath M, Patrick Gonzalez J, Grounds MD, Nichols A, Partridge T, Passini M, Sanarica F, Schnell FJ, Wells DJ, Yokota T, Young CS, Zhong Z, Spurney C, Spencer M, De Luca A, Nagaraju K, Aartsma-Rus A.

J Neuromuscul Dis. 2018;5(4):407-417. doi: 10.3233/JND-180324.

8.

Membrane Stabilization by Modified Steroid Offers a Potential Therapy for Muscular Dystrophy Due to Dysferlin Deficit.

Sreetama SC, Chandra G, Van der Meulen JH, Ahmad MM, Suzuki P, Bhuvanendran S, Nagaraju K, Hoffman EP, Jaiswal JK.

Mol Ther. 2018 Sep 5;26(9):2231-2242. doi: 10.1016/j.ymthe.2018.07.021. Epub 2018 Aug 27.

9.

The role of nitrite in muscle function, susceptibility to contraction injury, and fatigability in sickle cell mice.

Wang L, Almeida LEF, Kamimura S, van der Meulen JH, Nagaraju K, Quezado M, Wakim P, Quezado ZMN.

Nitric Oxide. 2018 Nov 1;80:70-81. doi: 10.1016/j.niox.2018.08.005. Epub 2018 Aug 14.

PMID:
30114530
10.

Synthesis, Characterization, and Function of an RNA-Based Transfection Reagent.

Jain HV, Boehler JF, Nagaraju K, Beaucage SL.

Curr Protoc Nucleic Acid Chem. 2018 Mar;72(1):4.81.1-4.81.29. doi: 10.1002/cpnc.51.

PMID:
29927123
11.

Muscle miRNAome shows suppression of chronic inflammatory miRNAs with both prednisone and vamorolone.

Fiorillo AA, Tully CB, Damsker JM, Nagaraju K, Hoffman EP, Heier CR.

Physiol Genomics. 2018 Sep 1;50(9):735-745. doi: 10.1152/physiolgenomics.00134.2017. Epub 2018 Jun 8.

12.

Organocatalytic synthesis of densely functionalized oxa-bridged 2,6-epoxybenzo[b][1,5]oxazocine heterocycles.

Gurubrahamam R, Nagaraju K, Chen K.

Chem Commun (Camb). 2018 Jun 8;54(47):6048-6051. doi: 10.1039/c8cc02565g.

PMID:
29799038
13.

Risk factors and disease mechanisms in myositis.

Miller FW, Lamb JA, Schmidt J, Nagaraju K.

Nat Rev Rheumatol. 2018 Apr 20;14(5):255-268. doi: 10.1038/nrrheum.2018.48. Review.

PMID:
29674613
14.

Skeletal, cardiac, and respiratory muscle function and histopathology in the P448Lneo- mouse model of FKRP-deficient muscular dystrophy.

Yu Q, Morales M, Li N, Fritz AG, Ruobing R, Blaeser A, Francois E, Lu QL, Nagaraju K, Spurney CF.

Skelet Muscle. 2018 Apr 6;8(1):13. doi: 10.1186/s13395-018-0158-x.

15.

Design, synthesis, neuroprotective, antibacterial activities and docking studies of novel thieno[2,3-d]pyrimidine-alkyne Mannich base and oxadiazole hybrids.

Triloknadh S, Venkata Rao C, Nagaraju K, Hari Krishna N, Venkata Ramaiah C, Rajendra W, Trinath D, Suneetha Y.

Bioorg Med Chem Lett. 2018 May 15;28(9):1663-1669. doi: 10.1016/j.bmcl.2018.03.030. Epub 2018 Mar 13.

PMID:
29602681
16.

Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle.

Novak JS, Hogarth MW, Boehler JF, Nearing M, Vila MC, Heredia R, Fiorillo AA, Zhang A, Hathout Y, Hoffman EP, Jaiswal JK, Nagaraju K, Cirak S, Partridge TA.

Nat Commun. 2018 Mar 23;9(1):1256. doi: 10.1038/s41467-018-03709-8.

17.

Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes.

Hoffman EP, Riddle V, Siegler MA, Dickerson D, Backonja M, Kramer WG, Nagaraju K, Gordish-Dressman H, Damsker JM, McCall JM.

Steroids. 2018 Jun;134:43-52. doi: 10.1016/j.steroids.2018.02.010. Epub 2018 Mar 8.

18.

Update on Standard Operating Procedures in Preclinical Research for DMD and SMA Report of TREAT-NMD Alliance Workshop, Schiphol Airport, 26 April 2015, The Netherlands.

van Putten M, Aartsma-Rus A, Grounds MD, Kornegay JN, Mayhew A, Gillingwater TH, Takeda S, Rüegg MA, De Luca A, Nagaraju K, Willmann R.

J Neuromuscul Dis. 2018;5(1):29-34. doi: 10.3233/JND-170288.

19.

Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle.

Novak JS, Hogarth MW, Boehler JF, Nearing M, Vila MC, Heredia R, Fiorillo AA, Zhang A, Hathout Y, Hoffman EP, Jaiswal JK, Nagaraju K, Cirak S, Partridge TA.

Nat Commun. 2018 Jan 15;9(1):208. doi: 10.1038/s41467-017-02206-8.

20.

Ryanodine channel complex stabilizer compound S48168/ARM210 as a disease modifier in dystrophin-deficient mdx mice: proof-of-concept study and independent validation of efficacy.

Capogrosso RF, Mantuano P, Uaesoontrachoon K, Cozzoli A, Giustino A, Dow T, Srinivassane S, Filipovic M, Bell C, Vandermeulen J, Massari AM, De Bellis M, Conte E, Pierno S, Camerino GM, Liantonio A, Nagaraju K, De Luca A.

FASEB J. 2018 Feb;32(2):1025-1043. doi: 10.1096/fj.201700182RRR. Epub 2018 Jan 3.

21.

Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle.

Novak JS, Hogarth MW, Boehler JF, Nearing M, Vila MC, Heredia R, Fiorillo AA, Zhang A, Hathout Y, Hoffman EP, Jaiswal JK, Nagaraju K, Cirak S, Partridge TA.

Nat Commun. 2017 Oct 16;8(1):941. doi: 10.1038/s41467-017-00924-7. Erratum in: Nat Commun. 2018 Jan 15;9(1):208. Nat Commun. 2018 Mar 23;9(1):1256.

22.

An amphipathic trans-acting phosphorothioate RNA element delivers an uncharged phosphorodiamidate morpholino sequence in mdx mouse myotubes.

Jain HV, Boehler JF, Verthelyi D, Nagaraju K, Beaucage SL.

RSC Adv. 2017;7:42519-42528. doi: 10.1039/C7RA04247G. Epub 2017 Sep 4.

23.

Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.

Echigoya Y, Lim KRQ, Trieu N, Bao B, Miskew Nichols B, Vila MC, Novak JS, Hara Y, Lee J, Touznik A, Mamchaoui K, Aoki Y, Takeda S, Nagaraju K, Mouly V, Maruyama R, Duddy W, Yokota T.

Mol Ther. 2017 Nov 1;25(11):2561-2572. doi: 10.1016/j.ymthe.2017.07.014. Epub 2017 Jul 28.

24.

Effect of endurance exercise on microRNAs in myositis skeletal muscle-A randomized controlled study.

Boehler JF, Hogarth MW, Barberio MD, Novak JS, Ghimbovschi S, Brown KJ, Alemo Munters L, Loell I, Chen YW, Gordish-Dressman H, Alexanderson H, Lundberg IE, Nagaraju K.

PLoS One. 2017 Aug 22;12(8):e0183292. doi: 10.1371/journal.pone.0183292. eCollection 2017.

25.

Improving Reproducibility of Phenotypic Assessments in the DyW Mouse Model of Laminin-α2 Related Congenital Muscular Dystrophy.

Willmann R, Gordish-Dressman H, Meinen S, Rüegg MA, Yu Q, Nagaraju K, Kumar A, Girgenrath M, Coffey CBM, Cruz V, Van Ry PM, Bogdanik L, Lutz C, Rutkowski A, Burkin DJ.

J Neuromuscul Dis. 2017;4(2):115-126. doi: 10.3233/JND-170217.

26.

Coexistence of hard palate carcinoma with tuberculosis: A rarity.

Verma SK, Srivastava A, Nagaraju K, Mishra AK, Goel MM.

J Cancer Res Ther. 2017 Jan-Mar;13(1):142-144. doi: 10.4103/0973-1482.174538.

27.

Annexin A2 links poor myofiber repair with inflammation and adipogenic replacement of the injured muscle.

Defour A, Medikayala S, Van der Meulen JH, Hogarth MW, Holdreith N, Malatras A, Duddy W, Boehler J, Nagaraju K, Jaiswal JK.

Hum Mol Genet. 2017 Jun 1;26(11):1979-1991. doi: 10.1093/hmg/ddx065.

28.

Mitochondria mediate cell membrane repair and contribute to Duchenne muscular dystrophy.

Vila MC, Rayavarapu S, Hogarth MW, Van der Meulen JH, Horn A, Defour A, Takeda S, Brown KJ, Hathout Y, Nagaraju K, Jaiswal JK.

Cell Death Differ. 2017 Feb;24(2):330-342. doi: 10.1038/cdd.2016.127. Epub 2016 Nov 11.

29.

Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children.

Hathout Y, Conklin LS, Seol H, Gordish-Dressman H, Brown KJ, Morgenroth LP, Nagaraju K, Heier CR, Damsker JM, van den Anker JN, Henricson E, Clemens PR, Mah JK, McDonald C, Hoffman EP.

Sci Rep. 2016 Aug 17;6:31727. doi: 10.1038/srep31727.

30.

OPN-a induces muscle inflammation by increasing recruitment and activation of pro-inflammatory macrophages.

Many GM, Yokosaki Y, Uaesoontrachoon K, Nghiem PP, Bello L, Dadgar S, Yin Y, Damsker JM, Cohen HB, Kornegay JN, Bamman MM, Mosser DM, Nagaraju K, Hoffman EP.

Exp Physiol. 2016 Oct 1;101(10):1285-1300. doi: 10.1113/EP085768. Epub 2016 Sep 24.

31.

Patients' perceptions about the implementation of Revised National Tuberculosis Control Programme of India.

Verma SK, Nagaraju K, Kant S, Kushwaha RA, Kumar S, Garg R.

Indian J Tuberc. 2016 Apr;63(2):86-90. doi: 10.1016/j.ijtb.2015.06.002. Epub 2016 Jun 4.

PMID:
27451816
32.

Effects on muscle tissue remodeling and lipid metabolism in muscle tissue from adult patients with polymyositis or dermatomyositis treated with immunosuppressive agents.

Loell I, Raouf J, Chen YW, Shi R, Nennesmo I, Alexanderson H, Dastmalchi M, Nagaraju K, Korotkova M, Lundberg IE.

Arthritis Res Ther. 2016 Jun 10;18(1):136. doi: 10.1186/s13075-016-1033-y.

33.

Muscle myeloid type I interferon gene expression may predict therapeutic responses to rituximab in myositis patients.

Nagaraju K, Ghimbovschi S, Rayavarapu S, Phadke A, Rider LG, Hoffman EP, Miller FW.

Rheumatology (Oxford). 2016 Sep;55(9):1673-80. doi: 10.1093/rheumatology/kew213. Epub 2016 May 23.

34.

Effect of the IL-1 Receptor Antagonist Kineret® on Disease Phenotype in mdx Mice.

Benny Klimek ME, Sali A, Rayavarapu S, Van der Meulen JH, Nagaraju K.

PLoS One. 2016 May 23;11(5):e0155944. doi: 10.1371/journal.pone.0155944. eCollection 2016.

35.

Expanding Diversity without Protecting Groups: (+)-Sclareolide to Indolosesquiterpene Alkaloid Mycoleptodiscin A and Analogues.

Nagaraju K, Chegondi R, Chandrasekhar S.

Org Lett. 2016 Jun 3;18(11):2684-7. doi: 10.1021/acs.orglett.6b01145. Epub 2016 May 16.

PMID:
27181938
36.

Airway Diseases Education and Expertise (ADEX ) in Pediatrics: Adaptation for Clinical Practice in India.

Paramesh H, Nagaraju K, Sukumaran TU, Agarkhedkar S, Bhakta S, Tilak R, Vijayasekaran D, Narayanan V, Mane A, Phansalkar A, Kadhe G.

Indian Pediatr. 2016 Feb;53(2):154-8.

PMID:
26897152
37.

Endurance Exercise Improves Molecular Pathways of Aerobic Metabolism in Patients With Myositis.

Munters LA, Loell I, Ossipova E, Raouf J, Dastmalchi M, Lindroos E, Chen YW, Esbjörnsson M, Korotkova M, Alexanderson H, Nagaraju K, Crofford LJ, Jakobsson PJ, Lundberg IE.

Arthritis Rheumatol. 2016 Jul;68(7):1738-50. doi: 10.1002/art.39624.

38.

Design, architecture and application of nanorobotics in oncology.

Saxena S, Pramod BJ, Dayananda BC, Nagaraju K.

Indian J Cancer. 2015 Apr-Jun;52(2):236-41. doi: 10.4103/0019-509X.175805. Review.

39.

The use of proteomic analysis to study trafficking defects in axons.

Fu X, Brown KJ, Rayavarapu S, Nagaraju K, Liu JS.

Methods Cell Biol. 2016;131:151-62. doi: 10.1016/bs.mcb.2015.06.009. Epub 2015 Sep 2.

PMID:
26794512
40.

Annexin A1 Deficiency does not Affect Myofiber Repair but Delays Regeneration of Injured Muscles.

Leikina E, Defour A, Melikov K, Van der Meulen JH, Nagaraju K, Bhuvanendran S, Gebert C, Pfeifer K, Chernomordik LV, Jaiswal JK.

Sci Rep. 2015 Dec 15;5:18246. doi: 10.1038/srep18246.

41.

A review on protein functionalized carbon nanotubes.

Nagaraju K, Reddy R, Reddy N.

J Appl Biomater Funct Mater. 2015 Dec 18;13(4):e301-12. doi: 10.5301/jabfm.5000231. Review.

PMID:
26660626
42.

Elusive sources of variability of dystrophin rescue by exon skipping.

Vila MC, Klimek MB, Novak JS, Rayavarapu S, Uaesoontrachoon K, Boehler JF, Fiorillo AA, Hogarth MW, Zhang A, Shaughnessy C, Gordish-Dressman H, Burki U, Straub V, Lu QL, Partridge TA, Brown KJ, Hathout Y, van den Anker J, Hoffman EP, Nagaraju K.

Skelet Muscle. 2015 Dec 1;5:44. doi: 10.1186/s13395-015-0070-6. eCollection 2015.

43.

Effect of genetic background on the dystrophic phenotype in mdx mice.

Coley WD, Bogdanik L, Vila MC, Yu Q, Van Der Meulen JH, Rayavarapu S, Novak JS, Nearing M, Quinn JL, Saunders A, Dolan C, Andrews W, Lammert C, Austin A, Partridge TA, Cox GA, Lutz C, Nagaraju K.

Hum Mol Genet. 2016 Jan 1;25(1):130-45. doi: 10.1093/hmg/ddv460. Epub 2015 Nov 12.

44.

Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies.

Albrecht I, Wick C, Hallgren Å, Tjärnlund A, Nagaraju K, Andrade F, Thompson K, Coley W, Phadke A, Diaz-Gallo LM, Bottai M, Nennesmo I, Chemin K, Herrath J, Johansson K, Wikberg A, Ytterberg AJ, Zubarev RA, Danielsson O, Krystufkova O, Vencovsky J, Landegren N, Wahren-Herlenius M, Padyukov L, Kämpe O, Lundberg IE.

J Clin Invest. 2015 Dec;125(12):4612-24. doi: 10.1172/JCI81031. Epub 2015 Nov 9.

45.

"Watching time tick by…": Decision making for Duchenne muscular dystrophy trials.

Peay HL, Scharff H, Tibben A, Wilfond B, Bowie J, Johnson J, Nagaraju K, Escolar D, Piacentino J, Biesecker BB.

Contemp Clin Trials. 2016 Jan;46:1-6. doi: 10.1016/j.cct.2015.11.006. Epub 2015 Nov 9.

46.

Understanding the origin of non-immune cell-mediated weakness in the idiopathic inflammatory myopathies - potential role of ER stress pathways.

Lightfoot AP, Nagaraju K, McArdle A, Cooper RG.

Curr Opin Rheumatol. 2015 Nov;27(6):580-5. doi: 10.1097/BOR.0000000000000212. Review.

PMID:
26335926
47.

TNF-α-Induced microRNAs Control Dystrophin Expression in Becker Muscular Dystrophy.

Fiorillo AA, Heier CR, Novak JS, Tully CB, Brown KJ, Uaesoontrachoon K, Vila MC, Ngheim PP, Bello L, Kornegay JN, Angelini C, Partridge TA, Nagaraju K, Hoffman EP.

Cell Rep. 2015 Sep 8;12(10):1678-90. doi: 10.1016/j.celrep.2015.07.066. Epub 2015 Aug 28.

48.

Immune-mediated pathology in Duchenne muscular dystrophy.

Rosenberg AS, Puig M, Nagaraju K, Hoffman EP, Villalta SA, Rao VA, Wakefield LM, Woodcock J.

Sci Transl Med. 2015 Aug 5;7(299):299rv4. doi: 10.1126/scitranslmed.aaa7322. Review.

49.

The use of urinary and kidney SILAM proteomics to monitor kidney response to high dose morpholino oligonucleotides in the mdx mouse.

Zhang A, Uaesoontrachoon K, Shaughnessy C, Das JR, Rayavarapu S, Brown KJ, Ray PE, Nagaraju K, van den Anker JN, Hoffman EP, Hathout Y.

Toxicol Rep. 2015;2:838-849.

50.

Smear correction of highly variable, frame-transfer CCD images with application to polarimetry.

Iglesias FA, Feller A, Nagaraju K.

Appl Opt. 2015 Jul 1;54(19):5970-5. doi: 10.1364/AO.54.005970.

PMID:
26193140

Supplemental Content

Loading ...
Support Center